Isabella Ochola-Oyier

Assessing the Impact of SARS-CoV-2 Spike Mutations on Antibody Binding: A Comparative Assessment of the Wuhan and JN.1 Variants' Full-Length Spikes in a Multiplex Luminex Assay.Waweru G, Nyakundi R, Kutima B, Owuor S, Konyino G, Gitonga J, Lugano D, Maina A, Musyoki J, Ochola L, Omondi M, Kariuki CK, Ogongo P, Mwachari C, Shee F, Agoti C, Sande C, Uyoga S, Kagucia E, Agweyu A, Bejon P, Scott JAG, Warimwe GM, Ochola-Oyier LI, Nyagwange J
Viruses, (2025). 17:

Induction of an early IFN-γ cellular response and high plasma levels of SDF-1α are inversely associated with COVID-19 severity and residence in rural areas in Kenyan patients.Wanjiku P, Orindi B, Kimotho J, Sayed S, Shah R, Saleh M, Mwacharo J, Maronga C, Olouch V, Karanu A, Shah J, Nneka Z, Ochola-Oyier LI, Abdi AI, Dunachie S, Bejon P, Nduati EW, Ndungu FM
PLoS One, (2025). 20:e0316967

Genomic and clinical epidemiology of SARS-CoV-2 in coastal Kenya: insights into variant circulation, reinfection, and multiple lineage importations during a post-pandemic wave.Lambisia AW, Katama EN, Moraa E, Mwita JM, Gallagher K, Mutunga M, Nyale E, Omungala J, Mwanga M, Murunga N, Nyiro J, Nyagwange J, Sande C, Bejon P, Githinji G, Dellicour S, Phan MVT, Cotten M, Ochola-Oyier LI, Holmes EC, Agoti CN
BMC Glob Public Health, (2025). 3:80

Emergence and transmission dynamics of the FY.4 Omicron variant in Kenya.Musundi S, Mwanga M, Lambisia A, Morobe JM, Murunga N, Moraa E, Ndwiga L, Cheruiyot R, Musyoki J, Mutunga M, Guzman-Rincon LM, Sande C, Mwangangi J, Bejon P, Ochola-Oyier LI, Nokes DJ, Agoti CN, Nyiro J, Githinji G
Virus Evol, (2025). 11:veaf035

The genome sequence of varicella-zoster virus (Varicellovirus humanalpha3) obtained by metagenomics from a patient presenting with an exanthem rash.Musundi S, Okanda D, Lambisia A, Morobe JM, Muthanje E, Ochola-Oyier LI, Carter DP, Agoti CN, Kiiru J, Githinji G
Microbiol Resour Announc, (2025). :e0024825

Stable Plasmodium falciparum merozoite surface protein-1 allelic diversity despite decreasing parasitaemia in children with multiple malaria infections.Yaa RM, Kimenyi KM, Palasciano HA, Obiero G, Ochola-Oyier LI
Malar J, (2025). 24:136

Identification of coxsackievirus A24 variant during an acute hemorrhagic conjunctivitis outbreak in coastal Kenya, 2024.Lambisia AW, Mwita Morobe J, Moraa E, Mwarumba S, Korir FKN, Seif Athman R, Kiptui R, Mbee M, Mugo N, Amoth P, Muange P, Houldcroft JC, Barasa E, Mwangangi J, Githinji G, Holmes CE, Ochola-Oyier LI, Agoti CN
Wellcome Open Res, (2025). 10:28

Rethinking the evidence on COVID-19 in Africa.Bejon P, Agweyu A, Ochola-Oyier LI, Hamaluba M, Kamuya D, Kinyanjui S, Barasa E
Lancet Infect Dis, (2025). 25:S1473-3099

Detection of low frequency artemisinin resistance mutations, C469Y, P553L and A675V, and fixed antifolate resistance mutations in asymptomatic primary school children in Kenya.Osoti V, Wamae K, Ndwiga L, Gichuki PM, Okoyo C, Kepha S, Keitany K, Kandie R, Aricha S, Kiplagat R, Mwandawiro C, Bejon P, Snow RW, Ochola-Oyier LI
BMC Infect Dis, (2025). 25:73

Regional action needed to halt antimalarial drug resistance in Africa.Martinez-Vega R, Ishengoma DS, Gosling R, Rosenthal PJ, Dondorp A, Barnes KI, Nsanzabana C, Djimde AA, Ochola-Oyier LI, Tibenderana J, Chimumbwa J, Golassa L, Kapologwe NA, Mbacham WF, Kamya MR, Fidock DA, Komatsu R, von Seidlein L, Dhorda M
Lancet, (2025). 405:7-10

Malaria Chemotherapeutics What Next for Africa.Ochola L, Gitaka J, Kanoi B, Kimani CN, Akala HM, Alfred MO, Ochola-Oyier LI, Ogutu B
Advanced Therapeutics, (2025). 8:2400453

Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya.Lugano D, Kutima B, Kimani M, Sigilai A, Gitonga J, Karani A, Akech D, Karia B, Ziraba AK, Maina A, Lambisia A, Omuoyo D, Mugo D, Lucinde R, Owuor S, Konyino G, Newman J, Bailey D, Nduati E, Githinji G, Agoti CN, Bejon P, Scott JAG, Agweyu A, Kagucia W, Warimwe GM, Sande C, Ochola-Oyier LI, Nyagwange J
BMC Infect Dis, (2024). 24:1474

ONT sequencing identifies a high prevalence of crt sensitive, triple mutant dhfr and single mutant dhps parasites within an ANC population in Nigeria.Adegbola AJ, Ndwiga L, Wamae K, Osoti V, Bolaji OO, Bejon P, Ochola-Oyier LI
Front Genet, (2024). 15:1470156

The mRNA content of plasma extracellular vesicles provides a window into molecular processes in the brain during cerebral malaria.Kioko M, Mwangi S, Pance A, Ochola-Oyier LI, Kariuki S, Newton C, Bejon P, Rayner JC, Abdi AI
Sci Adv, (2024). 10:eadl2256

A retrospective analysis of P. falciparum drug resistance markers detects an early (2016/17) high prevalence of the k13 C469Y mutation in asymptomatic infections in Northern Uganda.Ogwang R, Osoti V, Wamae K, Ndwiga L, Muteru K, Ningwa A, Tuju J, Kinyanjui S, Osier F, Marsh K, Bejon P, Idro R, Ochola-Oyier LI
Antimicrob Agents Chemother, (2024). 68:e0157623

Editorial: Malaria molecular epidemiology current situation in Africa.Tandoh KZ, Duah-Quashie NO, Raman J, Ochola-Oyier LI
Front Epidemiol, (2024). 4:1400612

Distinct transcriptomic signatures define febrile malaria depending on initial infective states, asymptomatic or uninfected.Kimenyi KM, Akinyi MY, Mwikali K, Gilmore T, Mwangi S, Omer E, Gichuki B, Wambua J, Njunge J, Obiero G, Bejon P, Langhorne J, Abdi A, Ochola-Oyier LI
BMC Infect Dis, (2024). 24:140

Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational study.Kimotho J, Sein Y, Sayed S, Shah R, Mwai K, Saleh M, Wanjiku P, Mwacharo J, Nyagwange J, Karanja H, Kutima B, Gitonga JN, Mugo D, Karanu A, Moranga L, Oluoch V, Shah J, Mutiso J, Mburu A, Nneka Z, Betti P, Mutinda WU, Issak Abdi A, Bejon P, Ochola-Oyier LI, Warimwe GM, Nduati EW, Ndungu FM
Wellcome Open Res, (2023). 8:350

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.Hamaluba M, Sang S, Orindi B, Njau I, Karanja H, Kamau N, Gitonga JN, Mugo D, Wright D, Nyagwange J, Kutima B, Omuoyo D, Mwatasa M, Ngetsa C, Agoti C, Cheruiyot S, Nyaguara A, Munene M, Mturi N, Oloo E, Ochola-Oyier L, Mumba N, Mauncho C, Namayi R, Davies A, Tsofa B, Nduati EW, Aliyan N, Kasera K, Etyang A, Boyd A, Hill A, Gilbert S, Douglas A, Pollard A, Bejon P, Lambe T, Warimwe G
Wellcome Open Res, (2023). 8:182

Low frequency of Plasmodium falciparum hrp2/3 deletions from symptomatic infections at a primary healthcare facility in Kilifi, Kenya.Okanda D, Ndwiga L, Osoti V, Achieng N, Wambua J, Ngetsa C, Lubell-Doughtie P, Shankar A, Bejon P, Ochola-Oyier LI
Front Epidemiol, (2023). 3:1083114